JBIO JBIO JADE101 — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by JBIO in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about JBIO's jade101 — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is JBIO's JADE101 — research and development expense?
- JBIO (JBIO) reported JADE101 — research and development expense of $15.42M in Q1 2026.
- How has JBIO's JADE101 — research and development expense changed year-over-year?
- JBIO's JADE101 — research and development expense increased by 57.9% year-over-year, from $9.77M to $15.42M.
- What does JADE101 — research and development expense mean?
- This metric represents the total operating costs incurred by the JADE101 segment to advance its pipeline of therapeutic candidates through preclinical and clinical development stages. It captures expenditures related to drug discovery, laboratory research, and the regulatory activities required to support investigational new drug applications. Monitoring this expense provides insight into the company's commitment to innovation and the capital intensity required to bring its specific autoimmune disease therapies to market.